TARGETED THERAPY FOR
COLORECTAL CANCER
Molecular testing in colorectal cancer does not just tell you what might work -- it tells you definitively what cannot work. RAS status, BRAF status, MSI/MMR, and HER2 results each determine a different treatment path.
Molecular Profile and Treatment Implications
| Molecular Finding | Frequency | Treatment Implication |
|---|---|---|
| RAS wild-type (no KRAS/NRAS mutation) | 50-60% | Eligible for anti-EGFR antibodies: cetuximab and panitumumab -- significant benefit in combination with chemotherapy |
| KRAS G12C mutation | 3-4% of CRC | Sotorasib or adagrasib approved -- first targetable KRAS mutation after decades considered undruggable |
| Other KRAS / NRAS mutations | 35-45% | Anti-EGFR antibodies contraindicated -- no benefit; bevacizumab plus chemotherapy is standard approach |
| BRAF V600E | 8-10% | Encorafenib + cetuximab -- BRAF inhibitor monotherapy causes EGFR feedback reactivation in CRC unlike melanoma |
| MSI-H / dMMR | 5% metastatic CRC | Pembrolizumab preferred first-line -- outperforms chemotherapy in this subgroup |
| HER2 amplification | 2-3% RAS/BRAF wild-type | Trastuzumab-based combinations and tucatinib -- emerging options in this small subgroup |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Targeted Therapy for Your Colorectal Cancer?
CancerFax reviews your RAS, BRAF, MSI, and HER2 results and connects you with GI oncologists experienced in molecular-guided colorectal cancer treatment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.